Neuren Pharmaceuticals Limited (ASX:NEU – Get Free Report) insider Joseph(Joe) Basile purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was acquired at an average price of A$11.99 ($7.74) per share, with a total value of A$59,950.00 ($38,677.42).
Neuren Pharmaceuticals Price Performance
Neuren Pharmaceuticals Company Profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome.
- Five stocks we like better than Neuren Pharmaceuticals
- Investing in Agriculture 101: How to Invest in Agriculture
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What Investors Need to Know to Beat the Market
- 5 Reasons Mullen Automotive is About to Turn a Corner
- How to Capture the Benefits of Dividend Increases
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.